Beneficial FGF21 function has encouraged many attempts to utilize it as a therapeutic agent to treat obesity-related comorbidities, such as type 2 diabetes mellitus and dyslipidemia. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.